REFERENCE
FDA.FDA Drug Safety Communication: abnormal heart rhthms associated with use of Anzemet (dolasetron mesylate). Internet Document: [2 pages], 17 Dec 2010. Available from: URL: http://www.fda.gov
Rights and permissions
About this article
Cite this article
Risk of torsade de pointes leads to labelling change for dolasetron. React. Wkly. 1333, 2 (2011). https://doi.org/10.2165/00128415-201113330-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-201113330-00002